Physician profile
Jasmine Pascoe
NPI 1164050837
$2,221.97
in general payments reported to CMS, 2019-2025
16 companies · $1,784 in 2025
The $1,784 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $438 · 2025: $1,784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,221.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $793.78 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $287.26 | 2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $275.58 | 2024-2025 | |
| Amgen INC. | $242.03 | 2025 | Uplizna |
| Genzyme Corporation | $232.13 | 2024-2025 | |
| Emd Serono, INC. | $119.76 | 2024 | |
| Biogen, INC. | $51.06 | 2025 | Tysabri, Vumerity |
| Lilly USA, LLC | $39.34 | 2025 | Kisunla |
| Genentech USA, INC. | $28.69 | 2025 | Ocrevus Zunovo |
| Eisai INC. | $28.41 | 2025 | |
| Pfizer INC. | $23.99 | 2025 | |
| Neurocrine Biosciences, INC. | $22.79 | 2025 | |
| Argenx US, INC. | $22.76 | 2025 | Vyvgart Hytrulo |
| Teva Pharmaceuticals USA, INC. | $19.82 | 2025 | Austedo Xr |
| Cycle Pharmaceuticals INC | $17.60 | 2025 | Bafiertam, Tascenso Odt |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tonix Medicines, INC. | $16.97 | 2025 | Zembrace Symtouch |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasmine Pascoe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.